Clinical Trial Signal Pricing
Public-data research intelligence

Trial movement awareness without the enterprise contract.

Monitor public clinical trial records, FDA safety sources, sponsor disclosures, literature, patents, grants, and global regulatory sources in one source-backed research feed.

Built for the gap below enterprise clinical intelligence

Enterprise life-sciences intelligence platforms are built for deep curated research, large teams, and annual procurement. Clinical Trial Signal serves the user who needs fast public-record awareness: what changed, where it changed, why it may matter, and where to verify it.

Enterprise platforms
Clinical Trial Signal
DataProprietary curated datasets
DataPublic-source monitoring
PricingAnnual contracts
PricingMonthly self-serve pricing
ScopeDeep pipeline / patent / regulatory / deal intelligence
ScopeDaily trial, safety, sponsor, literature, patent, and grant movement
Built forLarge-team workflows
Built forIndividual and small-team watchlists
Stack roleExpensive research stack
Stack roleSource-backed awareness layer

Sources monitored

ClinicalTrials.gov WHO ICTRP EU CTIS openFDA FAERS FDA recalls MedWatch DailyMed Drugs@FDA PubMed Europe PMC EDGAR PatentsView NIH RePORTER CMS Open Payments Federal Register EMA NICE PMDA WHO VigiAccess

Who this is for

Independent analysts

No more manual spreadsheets

Monitor trial movement and sponsor disclosures without rebuilding watchlists by hand every week.
Healthcare consultants

Faster source-backed client briefs

Pull what changed and where it changed, with primary-record links your client can audit.
Small biotech & BD teams

Track competitors and read-out timing

Watch competing programs, read-out dates, and sponsor 8-K language as it posts.
Journalists

Public-record changes worth deeper reporting

Status reversals, completion-date moves, recall classifications, FDA correspondence references in sponsor filings.
Investors and market watchers

Public clinical-development movement

Track registry, FDA, and sponsor-disclosure movement with clear caveats. Not investment advice.
Academic and nonprofit researchers

Disease-area research movement

Follow trials, literature, and grant activity across one feed, anchored to primary records.

What a signal looks like

Example signals. The cards below describe the shape of a signal from each source. Real signals on /trials, /safety, and /sponsors link directly to the primary public record.
Trial Movement Example signal Notable
Phase 3 GLP-1 obesity program — primary completion shifted
GLP-1 drug class · Phase 3 · Condition: Obesity
What changed. Registry record updated — primary completion moved later. Why it matters. Read-out timing shifts cascade through competitor positioning and analyst submission-timeline models.
Source type: ClinicalTrials.gov registry record Fields surfaced: status, primary completion date, last update posted
FDA / Safety Example signal High Attention
openFDA Drug Enforcement — Class II recall posted
openFDA Drug Enforcement · Recall class: II · Multiple lots
What changed. A Class II recall covering multiple lots was entered into openFDA enforcement records. Why it matters. Class II indicates temporary or reversible health consequences are possible; supply chains and prescribers track these closely.
Source type: openFDA Drug Enforcement endpoint Fields surfaced: classification, recall reason, lots, distribution pattern, status
Sponsor Disclosure Example signal Monitor
Public biotech sponsor — Form 8-K references FDA correspondence on Phase 2 program
SEC 8-K disclosure · Phase 2 oncology program · Sponsor-disclosed
What changed. A material-event filing reports receipt of FDA correspondence regarding the sponsor's Phase 2 program. Why it matters. Sponsor-disclosed FDA correspondence often precedes registry status changes by days to weeks.
Source type: SEC EDGAR Form 8-K filing Fields surfaced: item, filing date, narrative excerpt with FDA-correspondence reference
See live signals →

Live trial movement

What this feed shows. The most recently updated trials on ClinicalTrials.gov — status changes, primary-completion-date shifts, results posting, and new registrations — linked to the primary registry record with the field that moved and the previous and new values. Live records load below.
Search any drug, sponsor, or condition →

Evidence Room

Every record we ship carries the same source-backed contract — the fields a researcher needs to verify, cite, and re-audit. If a field can't be filled from the primary record, the signal does not ship.

The source-backed contract
SourceNamed primary public source (e.g. ClinicalTrials.gov registry, openFDA enforcement, SEC 8-K)
Source URLDeep link to the specific primary record (NCT page, openFDA record, EDGAR filing)
Source timestampWhen the primary record reports the change
Ingested timestampWhen Clinical Trial Signal observed the change
Previous valueThe exact prior field value from the primary record
New valueThe exact new field value from the primary record
CaveatWhat the change does not establish (e.g. registry date moves do not establish cause; FAERS reports do not establish causation or incidence)
Evidence record Example evidence record Notable
Trial primary-completion change · Phase 3 GLP-1 obesity (illustrative)
SourceClinicalTrials.gov registry
Source URLDeep link to the live NCT record (shown on real signals)
Source published2026-05-30T00:00:00Z
Ingested2026-05-30T04:12:48Z
Previous valuePrimaryCompletion = 2026-12-15
New valuePrimaryCompletion = 2027-06-15
Normalized signaltrial.primary_completion_shift · delta = +6 months · severity = notable
AI-assisted interpretationA 6-month shift on a lead Phase 3 read-out moves the sponsor's regulatory submission window out of 2026, with downstream implications for competing-program timing and BD windows. Driver not disclosed in the registry record.
Registry date moves do not establish cause. Possible drivers include enrollment, supply, protocol amendments, analytical plan changes, or safety review. The sponsor has not publicly disclosed a reason in the registry record.

Why not enterprise platforms?

Clinical Trial Signal is not a proprietary curated enterprise database. It is a lower-cost public-record movement layer — built to detect what changed in public sources, generate source-backed briefs you can hand to a colleague or client, and tell you where deeper, paid-database research is actually worth the effort. Enterprise platforms still own deep curated pipeline / patent / regulatory / deal datasets; we sit beside them as an awareness layer, not a replacement.

Choose your tier

Pro · $199/mo

Independent analyst, consultant, journalist

Best for individual researchers who need fast, source-backed public-record awareness.
  • Independent analysts and freelance researchers
  • Healthcare and life-sciences consultants
  • Journalists covering trials, FDA, or sponsor disclosure
  • Academic and nonprofit researchers
Choose Pro
Analyst Desk · $399/mo

Biotech investor, BD, competitive intelligence

Adds SEC EDGAR, USPTO patents, NIH RePORTER, CMS Open Payments, and sponsor-comparison dashboards.
  • Biotech and life-sciences investors
  • Corporate and biotech business-development teams
  • Competitive-intelligence and strategy functions
  • Small biotech and emerging-pharma teams
Choose Analyst Desk
Research Team · $699/mo · 5 seats

Multi-seat research desk, pharma team, consultancy

Adds WHO VigiAccess, NICE, PMDA, disease-area dashboards, Evidence Room exports.
  • Multi-seat sell-side and buy-side research desks
  • Pharma medical-affairs, R&D strategy, and CI teams
  • Consultancies serving multiple life-sciences clients
  • Disease-foundation and policy research groups
Choose Research Team

Pricing

Free
$0

Search public registries, see today's surfaced signals, follow live FDA alerts and recalls.

Analyst Desk · $399/mo
$399/month

Adds SEC EDGAR, USPTO patents, NIH RePORTER, CMS Open Payments, and wire feeds.

Research Team · $699/mo
$699/month

Adds WHO VigiAccess, NICE, PMDA, disease-area dashboards, Evidence Room exports. 5 seats included.

Compliance-safe positioning. Clinical Trial Signal provides public-data research intelligence. It is not medical advice, legal advice, regulatory advice, investment advice, or a pharmacovigilance system of record. Public adverse-event data may be incomplete, duplicated, unverified, and cannot establish causation or incidence. Signals are intended for research screening and should be reviewed by qualified professionals.